摘要
目的:探讨白疕软膏治疗银屑病的作用机理。
方法:实验采用5%心得安乳剂建立豚鼠银屑病样皮炎模型,观察白疙软膏对豚鼠银屑病样皮炎模型组织病理改变的影响;采用放射免疫法检测豚鼠银屑病样皮炎模型皮损中细胞因子IL-2、IL-6、IL-8的水平,观察白疕软膏对豚鼠银屑病样皮炎模型皮损中细胞因子的影响;采用MTT法研究了中药白疕方提取液及白疕方主要组成药物大黄、黄柏、黄精、苦参提取液对角质形成细胞系HaCaT细胞增殖的影响及对TNF-α刺激后的角质形成细胞系HaCaT细胞增殖的影响。
结果:白疕软膏对豚鼠银屑病样皮炎模型组织病理改变有影响,Baker评分白疕软膏组为2.70±0.67,与模型组6.20±1.42比较,差异有显著性(p<0.05),与对照组喜树碱软膏组3.00±0.58比较,差异无显著性(p>0.05)。白疕软膏对豚鼠银屑病样皮炎模型皮损中细胞因子水平有影响,豚鼠银屑病样皮炎模型皮损中IL-2、IL-6水平增高,与空白对照组比较,差异有显著性(p<0.05);白疕软膏组、喜树碱软膏组皮损中IL-2、IL-6水平降低,与模型组比较,差异有显著性(p<0.05)。细胞培养实验显示:中药白疕方提取液及白疕方主要组成药物大黄、黄柏、黄精、苦参提取液对角质形成细胞系HaCaT细胞增殖及对TNF-α刺激后的角质形成细胞系HaCaT细胞增殖均有抑制作用,且呈剂量依赖性。
结论:白疕软膏对豚鼠银屑病样皮炎模型组织病理改变有治疗作用,其作用机理可能是通过对角质形成细胞增殖的抑制及对细胞因子的调节而发挥作用。白疕软膏是治疗银屑病的有效外用制剂,值得进一步研究和推广。
Objective:The aim of this study is to investigate the effects and mechanisms of Baibi ointment for treating Psoriasis.
Methods: 5% propranolol emulsion was applied externally on the back of a guinea pig' s ear to produce the psoriasis-like dermatitis model to observe the effects of Baibi ointment on the histopathological changes of the model.Radioimmunoassay was used to observe the levels of cytokines like IL-2、IL—6 and IL-8, and the effects of the ointment to the cytokines. MTT method was used to study the effects of the extracts of the Baibi Formula and the extracts of its main components Huangjing , Kushen , Dahuang ,Huangbai, to the multiplication of HaCaT cells—one of the Malpighian cell line with and without stimulation of TNF-α.
Results:Baibi ointment showed some effects on the histopathological changes of the models. It showed that the Baibi ointment Group was 2.70±0.67 and the model group was 6.20±1.42 by Baker score,p<0.05;while compared with the control group-Camptothecine ointment group which was 3.00±0.58,p >0.05.Baibi ointment was effective to the levels of cytokines also.Increased levels of IL-2、IL-6 were showed in the model group,compare with the controlled blank group p<0.05, decreaed levies of IL-2>IL? were showed in the Baibi Ointment group and Camptothecine ointment group, compared with the model group, p < 0.05.Cell culture experiments showed that the extracts of the Baibi Formula and the extracts of its main components Dahuang, Kushen , Huangbai, Huangjing were effective in inhibiting the multiplication of HaCaT cells with or without the stimulation of TNF-αand the relationship between the two was dose dependent.
Conclusion:Baibi ointment has therapeutical effects on the histopathological changes of the models of psoriasis-like dermatitis in guinea pigs. The mechanism is probably by inhibiting the multiplication of the Malpighian cell and regulating the cytokines. Thus, Baibi ointment is an effective external preparation to treat psoriasis, and is worthy of deeper reasearch and generalization.
引文
[1]王侠生，廖康煌主编．杨国亮皮肤病学．上海：上海科学技术文献出版社，2005：505-508．
[2]黄畋，张淑芝，孙令．心得安涂药造成豚鼠耳部银屑病样病理变化．中华皮肤科杂志，1991，24(2)：96-97．
[3]Baker BS, Brent L,Valdimarsson H, et al.Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines．Br J Dermatol，1992，126：105-110．
[4]李元文，张丰川．专科专病名医临证经验丛书皮肤病．北京：人民卫生出版社，2002：270-340．
[5]金起凤．消银解毒汤治疗银屑病58例疗效观察．辽宁中医杂志，1983，7(6)：29-30．
[6]高学敏，钟赣生主编．临床中药学．石家庄：河北科学技术出版社，2005：266-922．
[7]魏志平，殷金珠，沈力．大黄素对角朊细胞体外增殖分化影响的研究．中国药理学通报，1998，4(2)：157-160．
[8]袁劲松，周利平，胡长发，等．中药对银屑病抗体搭桥角质形成细胞/单一核白细胞粘连的影响．中国中西医结合皮肤性病学杂志，2005，4(4)：240-241．
[9]田荻，秦建中．四种苦参生物碱对人角朊细胞增殖的影响．实用中西医结合杂志，1997，10(11)：1110-1111．
[10]Gaylarde PM. Psoriasiform changes in guinea-pig skin from propranolol.Clin Exp Dermatol,1978,3(2):157-160.
[11]李翠华，张弘，焦来文，等．喜树碱软膏联合派瑞松霜治疗慢性湿疹或神经性皮炎疗效观察．中国皮肤性病学杂志，2004，18(3)：147-148．
[12]颜克菊，冷丽娟．喜树碱治疗银屑病40例分析．河北医药2000，22(6)：459．
[13]陈祥生．银屑病的免疫发病机制与免疫治疗．国外医学皮肤性病 学分册，1997，23(1)：37-39．
[14]龚菲力主编．医学免疫学．北京：科学出版社，2004：72-81．
[15]Baker BS, Fry L. The immunology of psoriasis.Br J Dermatol,1992,126:1.
[16]Takematsu H,Tagami H.Interleukin 2,soluble interleukin 2 receptor,and interferon γ in the suction blister fluids from psoriatic skin.Arch Dermatol Res,1990,124:149.
[17]董萍云，蒋俊青，靳桂品．寻常型银屑病患者血清白介素-2水平测定．临床皮肤科杂志，2003，32(5)：251．
[18]赵庆利，刘玮等．银屑病患者皮损中IL-2抗原的检测．中华皮肤科杂志，1994，27(1)：31-32．
[19]王建琴，顾伟程等．银屑病皮损原位组化研究．中华皮肤科杂志，1994，27(5)：301-302．
[20]Eisenthal A,Kashtan H, Rabau M, et al.Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.Cancer Immunol Immunother, 1993, 36(2):101-107.
[21]Yoshizaki K,Kishimoto T.Interleukin 6.In:Luger TA.Neutrophil activating proteins in psoriasis.J Invest Dermatol,1992,98(2):241-247.
[22]Bonifati C, Carducci M, cordiali PP,et al. Correlated increases of tumor factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating fator levels in suntion blister fluids and sera of psoriasis patients-relationships with disease severity.Clin Exp Dermatol, 1994,19:383-387.
[23]Gilhar A, David M,Kalish RS, et al. In vivo effects of cytokines on psoriatic skin grafted on nude mice:involvement of the tumor necrosis factor(TNF) receptor. Clin Exp Immunol,1996,106(1):134-142.
[24]Bonifati C, Mussi A,D' Auria L, et al. Spontaneous release of leukemia inhibitor factor and oncostatin-M is increased in supernatants of short-term cultures from lesional psoriatic skin.Arcb Dermatol Res, 1998,290:9-13.
[25]Sticherling M, Sautier W,Schroder JM, et al.Interleukin-8 Plays its role at local levelin psoriasis vulgaris. Acta Derm Venereol, 1999,79:4-8.
[26]Jiang WY, Chattedee AD, Raychaudhuri SP,et al. Mastcell density and IL-8 expression in nonlesional and lesional psoriatic skin.Int J Dermatol 2001,40:699-703.
[27]郑淑云、张岩等．银屑病患者白介素8的观察．哈尔滨医科大学学报，1997，31(4)：309．
[28]Schroder JM, Gregory H,Young J, et al. Neutrophil-activ梐ting proteins in psoriasis. J Invest Dermatol, 1992,98:241-247.
[29]张开明，刘梅青，周敏等．银屑病患者白介素8含量测定．中华皮 肤科杂志，1995，28：319-320．
[30]Szell M, Bata-Csorgo Z, Koreck A, et al.Proliferating keratinocytes are putative sources of the psoriasis susceptibility-related EDA+(extra domain A of fibronectin) oncofetal fibronectin. J Invest Dermatol,2004,123: 537-546.
[31]Chodorowska G. Plasma concentrations of IFN-γ and TNF-α in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol,1998,10(2):147-151.
[32]张开明，尹国华，周敏，等．肿瘤坏死因子a在银屑病发病中的作用．中华皮肤科杂志，1993，26(3)：168-169．
[33]陈先进，张开明，尹国华，等．肿瘤坏死因子a对角质形成细胞产生白介素8和增殖活性的影响．中华皮肤科杂志，2002，35(4)：293-295．
[34]张云璧，瞿幸，牛福玲等．常用治疗银屑病的中药对肿瘤坏死因子a刺激后角质形成细胞生长及分泌白介素8的影响．中国中西医结合皮肤性病学杂志，2006，5(1)：18-20．
[35]Finch PW, Murphy F, Cardinale I, et al. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol, 1997,151:1619-1628.
[36]李常兴，张锡宝，吴志华．甲氨蝶呤与银屑病．岭南皮肤性病科杂志，2004，11(2)：200-203．
[37]李常兴，张锡宝，吴志华，等．甲氨蝶呤对银屑病患者皮损内VEGFmRNA影响的研究．中国皮肤性病学杂志，2005，19(9)：522-524．
[38]路又璐，秦建中．17味中药对培养的表皮细胞增殖的影响．临床皮肤科杂志，1996，4：202-204．
[1]Takematsu H,Tagami H.Interleukin 2 soluble interleukin 2 receptor and interferon-γ in the suction blister fluids from psoriatic skin. Arch Dermaatol Res,1990,282:149.
[2]Bjerke JR,Livden JK,Degre M,et al.Interferon in suction blister fluid from psoriasis lesion. Br J Dermatol,1983(3):295-299.
[3]Liven JX, Nilsen R, Bjerke JR, et al. In situ localization of interferons in psoriasis lesion. Arch Dermatol Res,1989,281(6):392-397.
[4]刘玮，赵庆利，张新华，等．IFN-γ诱导人正常皮肤表达银屑病皮损的表型．细胞与分子免疫学杂志，2000，16(2)：142．
[5] Chodorowska G. Plasma concentrations of IFN-γ and TNF-α in psoriatic patients before and after local treatment with dithranol ointment.J Eur Acad Dermatol Venereol,1998,10(2):147-151.
[6]张开明，尹国华，周敏，等．肿瘤坏死因子α在银屑病发病中的作用．中华皮肤科杂志，1993，26(3)：168-169．
[7]张云璧，瞿幸，牛福玲等．常用治疗银屑病的中药对肿瘤坏死因子α刺激后角质形成细胞生长及分泌白介素8的影响．中国中西医结合皮肤性病学杂志，2006，5(1)：18-20．
[8]Groves RW, Allen MH, Barker JN, et al.Endothelial leucocyte adhesion molecule-1 expression in cutaneous inflammation. Br J Dermatol, 1991,124:117-123.
[9]Nickoloff BJ, Karabin GD,Baker JNWN,et al.Cellular Localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis.Am J Pathol,1991,138:129-140.
[10]张士发，林俊萍，王雅坤，等．寻常型银屑病患者皮损TNF受体和ICAM-1及淋巴细胞功能相关抗原的表达．中华皮肤科杂志，1998，31(2)：84-85．
[11]Ameglio F, Bonifati C, Pietravalle M, et al.Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology, 1994,189(4):359-363.
[12] Keane J,Gershon S,Wise RP,et al.Tuberculosis associated with infliximab,a tumor necrosis factor alpha neutralizing agent. N Engl J Med,2001,345(15):1098-1104.
[13]李先平，李晶，王皓，等．银屑病生物治疗研究进展．中国医药生物技术，2007，2(3)：207-211．
[14]LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin,2001,19(4):617-635.
[15]Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther,2002, 301(2): 418-426.
[16]Schreiber AB, Winkler ME, Derynck R. Transforming Growth factor-α:a more potent angiogenic mediator than epidermal growth factor.Science,1986,232:1250.
[17]Nanney LB. Epidermal and dermal effects of epidermal growth factor during wound repair.J Invest Dermatol,1990,94:624.
[18]冯捷，郑玉萍，苏宝山等．转化生长因子α在银屑病患者角朊细胞中的异常表达．中华皮肤科杂志，1996，29(2)104-105．
[19]刘振祥．银屑病发病的分子机理．现代皮肤性病学进展．合肥：安徽科技出版社出版，1997．380-387．
[20]Van de Kerkhof PC,Rulo HF, Van Pelt JP, et al.Expression of endoglin in the transition between psoriatic uninvolved andi nvolved skin.Acta Derm Venereol,1998,78(1):19-21.
[21]高春芳，顾军，郑茂荣，等．银屑病外周血中转化生长因子β1水平的动态观察．临床皮肤科杂志，2002，31(7)：419-420．
[22]马小玲，季必华，慈超等．转化生长因子β及其受体Ⅰ、Ⅱ在银屑病皮损中的表达．中国皮肤性病学杂志，2003，17(6)：374．
[23]朱可建，周伟芳，劳力民等．银屑病患者外周血单核细胞向树突状细胞分化能力的研究.中华皮肤科杂志，2002，35(2)：88-89．
[24]Aasdullah K,Sterry W, Stephane K,et al.IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy:a new therapeutic approach.J Clin Invest, 1998,101:783-794.
[25]Kulke R, T dt-Pingel I, Rademacher D, et al. Co-localized overexpression of GRO-α and IL-8mRNA is restricted to the suprapapillary layers of psoriatic lesions. J Invest Dermatol, 1996,106(3):526-530.
[26]Gillitzer R, Ritter U, Spandau U, et al. Differential expression of GRO-α and IL-8mRNA in psoriasis:a model for neutrophil migration and accumulation in vivo.J Invest Dermatol, 1996, 107(5): 778-782.
[27]Kojima T, Cromie MA, Fisher GJ, et al.GRO-α mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo,but not in cultured keratinocytes. J Invest Dermatol,1993, 101(6):767-772.
[28]Goebeler M, Toksoy A, Spandau U,et al.The C-X-C Chemokine Mig is highly expressed in the papillae of psoriatic lesions.J Pathol, 1998,184(1): 89-95.
[29]Rottman J B,Smith T L,Ganley K G,et al.Potential role of the chemokine receptors CXCR3,CCR4,and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. Lab Invest, 2001,81(3):335-347.
[30]Wakugawa M,Nakamura K,Kakinuma T,et al.CC chemokine receptor 4 expression on peripheral blood CD4~+ T cells reflects disease activity of atopic dermatitis.J Invest Dermatol,2001,117(2):188-196.
[31] Stoof T J,Flier J,Sampat S, et al.The antipsoriatic drug dimethyl-fumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells.Br J Dermatol, 2001, 144(6):1114-1120.
[32]Homey B, Dieu-Nosjean M C, Wiesenborn A, et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol,2000,164(12):6621-6632.
[33]Dieu-Nosjean MC, Massacrier C, Homey B, et al. Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors.J Exp Med, 2000, 192(5):705-718.
[34]Nakamura K,Williams IR,Kupper TS,et al.Keratinocyte-derived monocyte
[35]黎志刚，郑学毅，曾仁山，等．紫外线治疗前后银屑病患者皮损角质形成细胞趋化因子CCL/RANTES的表达．临床皮肤科杂志，2007，36(5)：292-293．
[36]Fukuoka M,Ogino Y,Sato H,et al.RANTES expression in psoriatic skin,and regulation of RANTES and IL-8 prodution in cultured epidermal keratinocytes by active vitamin D3(tacalcitol). Br J Dermatol,1998,138(1):63-70.
[37]Arakawa S, Hatano Y, Katagiri K, et al.Effects of ultraviolet Birradiation on the production of regulated upon activation normal T-cell expressed and secreted protein in cultured human epidermal keratinocytes. Arch DermatolRes,2006,297(8):377-380.
[38]Wei L, Debets R, Hegmans JJ, et al. IL-lbeta and IFN-gamma induce the regenerative epidermal phenotype of psoriasis in the transwell skin organ culture system. IFN-gamma up regulates the expression of keratin 17 and keratinocyte transglutaminase via endogenous IL? production. J Pathol,1999,187(3):358-364.
[39]el Barnawi NY,Giasuddin AS, Ziu MM, et al.Serum cytokine levels in psoriasis vulgaris. Br J Biomed Sci,2001,58(1):40-44.
[40]Schon M, Behmenburg C, Denzer D,et al.Pathogenic function of IL-1beta in psoriasiform skin lesions of flakyskin (fsn/fsn)mice. Clin Exp Immunol, 2001, 123(3):505-510.
[41]龚菲力主编．医学免疫学．北京：科学出版社，2004：72-81．
[42]Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol, 1992,126:1.
[43]Takematsu H, Tagami H.Interleukin 2,soluble interleukin 2 receptor, and interferon γ in the suction blister fluids from psoriatic skin. Arch Dermatol Res,1990,124:149.
[44]董萍云，蒋俊青，靳桂品．寻常型银屑病患者血清白介素-2水平测定．临床皮肤科杂志，2003，32(5)：251．
[45]赵庆利，刘玮等．银屑病患者皮损中IL-2抗原的检测．中华皮肤科杂志，1994，27(1)：31-32．
[46]王建琴，顾伟程等．银屑病皮损原位组化研究．中华皮肤科杂志，1994，27(5)：301-302．
[47]Eisenthal A, Kashtan H, Rabau M, et al. Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.Cancer Immunol Immunother,1993,36(2):101-107.
[48]Yoshizaki K, Kishimoto T.Interleukin 6.In:Luger TA.Neutrophil activating proteins in psoriasis. J Invest Dermatol,1992,98(2):241-247.
[49]Bonifati C,Carducci M,cordiali PP,et al.Correlated increases of tumor factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating fator levels in suntion blister fluids and sera of psoriasis patients-relationships with disease severity.Clin Exp Dermatol,1994,19:383-387.
[50]Gilhar A, David M,Kalish RS, et al. In vivo effects of cytokines on psoriatic skin grafted on nude mice:involvement of the tumor necrosis factor(TNF) receptor. Clin Exp Immunol, 1996,106(1):134-142.
[51] Bonifati C ,Mussi A,D' Auria L, et al. Spontaneous release of leukemia inhibitor factor and oncostatin-M is increased in supernatants of short-term cultures from lesional psoriatic skin. Arcb Dermatol Res,1998,290:9-13.
[52]Sticherling M,Sautier W, Schroder JM, et al.Interleukin-8 Plays its role at local levelin psoriasis vulgaris. Acta Derm Venereol, 1999,79:4-8.
[53]Jiang WY,Chattedee AD,Raychaudhuri SP, et al.Mastcell density and IL-8 expression in nonlesional and lesional psoriatic skin. Int J Dermatol 2001,40:699-703.
[54]郑淑云，张岩，商刚，等．银屑病患者白介素8的观察．哈尔滨医科大学学报，1997，31(4)：309-310．
[55]Schroder JM, Gregory H, Young J, et al. Neutrophil- activating proteins in psoriasis. J Invest Dermatol, 1992,98:241-247.
[54]张开明，刘梅青，周敏，等．银屑病患者白介素8含量测定．中华皮肤科杂志，1995，28：319-320．
[56]Asadullah K, Sterry W, Stephanek K, et al.IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy :a new therapeutic approach. J Clin Invest, 1998,101:783-794.
[58]Asadullah K,Docke WD,Ebeling M,et al.Interleukin 10 treatment of psoriasis:clinical results of a phase 2 trial.Arch Dermatol,1999,135:187-192.
[59] Friedrich M,Docke WD,Klein A,et al. Immunomodulation A,et al.Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol,2002,118:672-677.
[60]Reich K,Garbe C,Blaschke V,et al. Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation,down regulation of the epidermal interleukin-8/CXCR2 pathway and normalization of kerationcyte maturation. J Invest Dermatol,2001,116:319-329.
[61]Seifert M,Sterry W,Effenberger E,et al. The antipsoriatic activity of IL-10 is rather caused by effects on peripheral blood cells than by a direct effect on human keatinocytes. Arch Dermatol Res,2000,292:164-172.
[62] Ruckert R,Asadulah K,Seifert M,et al.Inhibition of keratinocyte apoptosis by IL-15:A new parameter in the pathogenesis of psoriasis. J Immunol,2000,165(4):2240-50.
[63]Villadsen L S,Schuuman J,Beursken F,et al. Resolution of psoriasis upon blockade of IL?5 biological activity in a xenograft mouse mode.J Clin Invest,2003,112(10):1571-1580.
[64]张国龙，张胜权，严开林等．IL-15在寻常型银屑病患者皮损中的表达．安徽医科大学学报，2006，41(4)：450．
[65]Ohta Y,Hamada Y,Katsuoka K. Expression of IL-18 inpsoriasis. Arch Dermatol Res,2001,293(7):334-342.
[66]Fickenscher H,Hor S,Kupers H,et al.The interleukin-10 family of cytokines. Trends Immunol,2002,23:89-96.
[67]樊平申，付萌，廖文俊等．豚鼠银屑病样动物模型皮损中IL-20的表达水平及反义寡核苷酸基因治疗．中国皮肤性病学杂志，2002，16(6)：363-365．
[68]Blumberg H, Conklin D, Xu WF, et al Interleukin 20 discovery. receptor identification and role in epidermal function.Cell,2001,104(1):9—19.
[69]Romer J, Hasselager E, Norby PL, et al. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol, 2003,121:1306-1311.
[1]于锡江．近十年中医药治疗银屑病概况．山东中医杂志，1994，13(3)：141．
[2]Koo J, Arain S.Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol, 1998, 134(11):1388-1393.
[3]李元文，张丰川．专科专病名医临证经验丛书皮肤病．北京：人民卫生出版社，2002：270-340．
[4]金起凤．消银解毒汤治疗银屑病58例疗效观察．辽宁中医杂志，1983，7(6)：29-30．
[5]龚景林．消银饮治疗银屑病100例．湖南中医杂志，1996，12(2)34．
[6]陈苏．消银方治疗银屑病．山东中医志，1998，17(11)：499-500．
[7]张小静．消银丸治疗银屑病45例．中医研究，2006，19(11)：42．
[8]孔岩．郁金银屑片治疗寻常型银屑病疗效观察.基层医学论坛，2003，7(6)：508．
[9]胡敢，薛茂，王正元．银杏叶片与沙丁胺醇联合治疗寻常型银屑病69例．中华皮肤科杂志，2001，34(2)：107．
[10]陈红，王思平．用复方青黛胶囊治疗寻常型银屑病的疗效观察及其对血清IL-2、IL-8的影响．中药材，2004，27(11)：886．
[11]贾中华．银屑灵冲剂治疗寻常型银屑病．山东中医杂志，1998，17(3)：111．
[12]王水电，张子琦．复方丹参静滴治疗银屑病32例疗效观察．现代中西医结合杂志，2003，12(3)：245．
[13]王丹，张国学，黎兆军．葛根素、丹参注射液治疗寻常型银屑病的疗效比较．宁夏医学杂志，2004，26(1)：51．
[14]杨西群，吕晓雅，杜宇等．蝮蛇抗栓酶静脉滴注治疗银屑病104例疗效观察．中国皮肤性病学杂志，1999，13(3)：185．
[15]周毅成，李鹤玉，张峰等．华蟾素治疗寻常型银屑病疗效观察．中华皮肤科杂志，2000，33(2)：128．
[16]周淑维，宋坪，刘瓦利等．清开灵注射液治疗银屑病血热证观察．中国中医基础医学杂志，2003，9(11)：37．
[17]赵振宇，李振化，李祥．双黄连粉针剂配合皮炎二号冲剂治疗银屑病．天津药学，2000，12(2)：51．
[18]袁耕．灯盏花素治疗66例银屑病．中华皮肤科杂志，1999，32(2)：135．
[19]杨素梅．甘利欣注射液治疗银屑病86例．中国中医急症，2002，11(3)：226．
[20]张育善，姚志道。自制复方青黛软膏治疗银屑病36例．皮肤病与性病，994，6(2)：32-33．
[21]张立新，杨顶权，宋佩华，等．普连膏在银屑病治疗中的应用．中医外治杂志，2000，9(5)：22-23．
[22]宋智琦，林熙然．外用莪术油霜剂治疗银屑病．中华皮肤科杂志，1998，31(2)：124-125．
[8]刘利红．自制消银油治疗银屑病68例．中医外治杂志，2003，12(1)：48．
[24]李雪君，宋占营．自拟狠毒散擦洗治疗银屑病57例．浙江中医杂志，1996，31(2)：70．
[25]刘卫兵，王梦柏，毛秀保．中药泡浴治疗银屑病78例．人民军医，998，41(2)：106-107．
[26]王静平，唐秀程．皮炎宁酊治疗银屑病23例．中国疗养医学，2001，10(2)：78．
[27]尚志英，曹沛德．自血穴位注射治疗银屑病128例．山东中医杂志，1998，17(3)：121．
[28]张秀丽．中医埋线治疗寻常型银屑病临床观察．四川中医，2005，23(4)：74．
[29]田洪青，路麒，王霞．心理治疗寻常型银屑病疗效观察．中国皮肤性病学杂志，2001，15(4)：246．
[30]丁维俊，王宇，陈晓玲，等．银屑病不同时期与证型的红细胞免疫功能研究．成都中医药大学学报，2004，27(4)：33-35．
[31]李冠勇，刘华昌．银屑病中医分型与血小板指数及微循环的关系．新中医，1997，29(2)：38-39．
[32]彭振辉，张美芳等．银屑病中医分型血清TGF β、TNF α的生物测定．中国皮肤性病学杂志，2000，14(1)：2-3．
[33]黄军丽．银屑病辨证分型与血脂及载脂蛋白的关系．前卫医药杂志，1999，16(6)：35．
[34]林瑞奋，肖明辉，王斗训．三藤汤治疗寻常型银屑病临床及免疫学研究．福建中医学院学报，2000，10(3)：8-10．
[35]张晓杰．寻常型银屑病辨证论治的研究．山东中医药大学学报，1997，21(2)：110-114．
[36]骆丹，徐文严，李锡林等．PUVA照射与青黛丸口服对银屑病患者血CAMP、CGMP、SOD及LPO含量的影响．中华皮肤科杂志，1997，30(2)：105-107．
[37]单筠筠，宋秀祖，尉晓冬，等．银屑号治疗寻常性银屑病临床疗效观察及相关细胞因子检测．中国中西医结合皮肤性病学杂志，2006，5(2)：87-88．
[38]范斌，李斌，沈健雄，等．凉血和活血中药对银屑病患者不同时期细胞因子的影响．中国中西医结合皮肤性病学杂志，2006，5(2)：70-71．
[39]吴京海，杨思源，金岚，等．丹参素对银屑病患者外周血单个核细胞粘附分子表达的影响．上海医科大学学报，1998，25(1)：47-48．
[40]吴晓霞，贾红声．愈银方治疗寻常型银屑病的实验研究．河北中医，2003，25(7)：559．
[41]白英华，田静，金春林．凉血四根提取物对实验性鼠阴道上皮细胞过度增殖的影响．中国中西医结合皮肤性病学杂志，2006，5(3)：145．
[42]王乖娟，刘卫兵，荆鲁华等．银屑宁胶囊对心得安致豚鼠银屑病样皮损NO和MDA水平的影响．中国中西医结合皮肤性病学杂志，2005，4(3)：166．
[43]刘波，李云兴，韩蕾，等．银屑灵抗炎及抗免疫作用的研究．辽宁中医杂志，1999，26(1)：37．
[44]辛红，孙晓慧，李颖奎，等．复方青黛胶囊对人角朊细胞增殖的影响．中国皮肤性病学杂志，1996，10(3)：147．
[45]袁劲松，周利平，胡长发，等．中药对银屑病抗体搭桥角质形成细胞/单一核 白细胞粘连的影响．中国中西医结合皮肤性病学杂志，2005，4(4)：240-241．
[46]张云璧，瞿幸，牛福玲．常用治疗银屑病的中药对肿瘤坏死因子-α刺激后角质形成细胞生长及分泌白介素IL-8的影响．中国中西医结合皮肤性病学杂志，2006，5(1)：18．